Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Lymphopenia and DMTs for relapsing forms of MS: Considerations for the treating neurologist.

Fox EJ, Buckle GJ, Singer B, Singh V, Boster A.

Neurol Clin Pract. 2019 Feb;9(1):53-63. doi: 10.1212/CPJ.0000000000000567. Review. Erratum in: Neurol Clin Pract. 2019 Jun;9(3):184.

2.

Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis.

Healy BC, Buckle GJ, Ali EN, Egorova S, Khalid F, Tauhid S, Glanz BI, Chitnis T, Guttmann CRG, Weiner HL, Bakshi R.

J Neuroimaging. 2017 Sep;27(5):481-485. doi: 10.1111/jon.12433. Epub 2017 Mar 6.

3.

An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy.

Carruthers RL, Rotstein DL, Healy BC, Chitnis T, Weiner HL, Buckle GJ.

Mult Scler. 2014 Sep;20(10):1381-90. doi: 10.1177/1352458514535282. Epub 2014 May 22.

PMID:
24852928
4.

JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis.

Chalkias S, Dang X, Bord E, Stein MC, Kinkel RP, Sloane JA, Donnelly M, Ionete C, Houtchens MK, Buckle GJ, Batson S, Koralnik IJ.

Ann Neurol. 2014 Jun;75(6):925-34. doi: 10.1002/ana.24148. Epub 2014 Jun 10.

5.

An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity.

Ottoboni L, Keenan BT, Tamayo P, Kuchroo M, Mesirov JP, Buckle GJ, Khoury SJ, Hafler DA, Weiner HL, De Jager PL.

Sci Transl Med. 2012 Sep 26;4(153):153ra131.

6.

Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: a longitudinal study.

Moodie J, Healy BC, Buckle GJ, Gauthier SA, Glanz BI, Arora A, Ceccarelli A, Tauhid S, Han XM, Venkataraman A, Chitnis T, Khoury SJ, Guttmann CR, Weiner HL, Neema M, Bakshi R.

J Neurol Sci. 2012 Apr 15;315(1-2):49-54. doi: 10.1016/j.jns.2011.11.040. Epub 2011 Dec 28.

7.

A 3T MR imaging investigation of the topography of whole spinal cord atrophy in multiple sclerosis.

Klein JP, Arora A, Neema M, Healy BC, Tauhid S, Goldberg-Zimring D, Chavarro-Nieto C, Stankiewicz JM, Cohen AB, Buckle GJ, Houtchens MK, Ceccarelli A, Dell'Oglio E, Guttmann CR, Alsop DC, Hackney DB, Bakshi R.

AJNR Am J Neuroradiol. 2011 Jun-Jul;32(6):1138-42. doi: 10.3174/ajnr.A2459. Epub 2011 Apr 28.

8.

The relationships among MRI-defined spinal cord involvement, brain involvement, and disability in multiple sclerosis.

Cohen AB, Neema M, Arora A, Dell'oglio E, Benedict RH, Tauhid S, Goldberg-Zimring D, Chavarro-Nieto C, Ceccarelli A, Klein JP, Stankiewicz JM, Houtchens MK, Buckle GJ, Alsop DC, Guttmann CR, Bakshi R.

J Neuroimaging. 2012 Apr;22(2):122-8. doi: 10.1111/j.1552-6569.2011.00589.x. Epub 2011 Mar 29.

9.

Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis.

Stankiewicz JM, Glanz BI, Healy BC, Arora A, Neema M, Benedict RH, Guss ZD, Tauhid S, Buckle GJ, Houtchens MK, Khoury SJ, Weiner HL, Guttmann CR, Bakshi R.

J Neuroimaging. 2011 Apr;21(2):e50-6. doi: 10.1111/j.1552-6569.2009.00449.x.

10.

Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study.

Gauthier SA, Glanz BI, Mandel M, Tsagkaropoulos A, Neema M, Stankiewicz J, Arora A, Duan Y, Liptak Z, Egorova S, Buckle GJ, Bakshi R, Guttmann CR, Khoury SJ, Weiner HL.

J Neurol Sci. 2009 Sep 15;284(1-2):116-9. doi: 10.1016/j.jns.2009.04.020. Epub 2009 May 9.

PMID:
19428028
11.

Rate of brain atrophy in benign vs early multiple sclerosis.

Gauthier SA, Berger AM, Liptak Z, Duan Y, Egorova S, Buckle GJ, Glanz BI, Khoury SJ, Bakshi R, Weiner HL, Guttmann CR.

Arch Neurol. 2009 Feb;66(2):234-7. doi: 10.1001/archneurol.2008.567.

PMID:
19204160
12.

Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis.

Neema M, Arora A, Healy BC, Guss ZD, Brass SD, Duan Y, Buckle GJ, Glanz BI, Stazzone L, Khoury SJ, Weiner HL, Guttmann CR, Bakshi R.

J Neuroimaging. 2009 Jan;19(1):3-8. doi: 10.1111/j.1552-6569.2008.00296.x.

13.

Spinal cord lesions and clinical status in multiple sclerosis: A 1.5 T and 3 T MRI study.

Stankiewicz JM, Neema M, Alsop DC, Healy BC, Arora A, Buckle GJ, Chitnis T, Guttmann CR, Hackney D, Bakshi R.

J Neurol Sci. 2009 Apr 15;279(1-2):99-105. doi: 10.1016/j.jns.2008.11.009.

14.

Neuroimaging in multiple sclerosis.

Ali EN, Buckle GJ.

Neurol Clin. 2009 Feb;27(1):203-19, ix. doi: 10.1016/j.ncl.2008.09.012. Review.

PMID:
19055980
15.

Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale.

Bakshi R, Neema M, Healy BC, Liptak Z, Betensky RA, Buckle GJ, Gauthier SA, Stankiewicz J, Meier D, Egorova S, Arora A, Guss ZD, Glanz B, Khoury SJ, Guttmann CR, Weiner HL.

Arch Neurol. 2008 Nov;65(11):1449-53. doi: 10.1001/archneur.65.11.1449.

16.

CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial.

Viglietta V, Bourcier K, Buckle GJ, Healy B, Weiner HL, Hafler DA, Egorova S, Guttmann CR, Rusche JR, Khoury SJ.

Neurology. 2008 Sep 16;71(12):917-24. doi: 10.1212/01.wnl.0000325915.00112.61.

PMID:
18794494
17.

Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein.

O'Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bettelli E, Xu C, Robinson WH, Cherry SV, Bar-Or A, Banwell B, Fukaura H, Fukazawa T, Tenembaum S, Wong SJ, Tavakoli NP, Idrissova Z, Viglietta V, Rostasy K, Pohl D, Dale RC, Freedman M, Steinman L, Buckle GJ, Kuchroo VK, Hafler DA, Wucherpfennig KW.

Nat Med. 2007 Feb;13(2):211-7. Epub 2007 Jan 12.

18.
19.

Immunosuppressive therapy for multiple sclerosis.

Gauthier SA, Buckle GJ, Weiner HL.

Neurol Clin. 2005 Feb;23(1):247-72, viii-ix. Review. No abstract available.

PMID:
15661097
20.

Activated CD8+ T cells in secondary progressive MS secrete lymphotoxin.

Buckle GJ, Höllsberg P, Hafler DA.

Neurology. 2003 Feb 25;60(4):702-5.

PMID:
12601116
21.

HTLV-I-infected T cells evade the antiproliferative action of IFN-beta.

Smith D, Buckle GJ, Hafler DA, Frank DA, Höllsberg P.

Virology. 1999 May 10;257(2):314-21.

22.

Direct analysis of viral-specific CD8+ T cells with soluble HLA-A2/Tax11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy.

Bieganowska K, Höllsberg P, Buckle GJ, Lim DG, Greten TF, Schneck J, Altman JD, Jacobson S, Ledis SL, Hanchard B, Chin J, Morgan O, Roth PA, Hafler DA.

J Immunol. 1999 Feb 1;162(3):1765-71.

23.

HTLV-I-induced T-cell activation.

Buckle GJ, Hafler DA, Höllsberg P.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S107-13. Review.

PMID:
8797712
24.

Lack of JC viral genomic sequences in multiple sclerosis brain tissue by polymerase chain reaction.

Buckle GJ, Godec MS, Rubi JU, Tornatore C, Major EO, Gibbs CJ Jr, Gajdusek DC, Asher DM.

Ann Neurol. 1992 Dec;32(6):829-31.

PMID:
1335225
25.

Belgrade virus: a new hantavirus causing severe hemorrhagic fever with renal syndrome in Yugoslavia.

Gligic A, Dimkovic N, Xiao SY, Buckle GJ, Jovanovic D, Velimirovic D, Stojanovic R, Obradovic M, Diglisic G, Micic J, et al.

J Infect Dis. 1992 Jul;166(1):113-20.

PMID:
1351508

Supplemental Content

Loading ...
Support Center